EXHIBIT B

EXHIBIT B

As consideration for Institution's performance of the Study, Company shall pay Institution $16,701 per subject for the actual number of subjects who complete the Study. Company will pay for completed visits for patients that do not complete the trial, in accordance with the following payment schedule. These amounts include all applicable overheads due to Institution. Company shall also reimburse Institution for its initial IRB review and approval fee, subsequent annual IRB renewal fees, and, if applicable, fees for IRB review and approval of each material Protocol amendment.

Payment #1: $4,875 upon execution of this Agreement and initiation of the Study, *provided that* the following documents have been received by Company: (i) signed Protocol signature page; (ii) signed FDA form 1572; (iii) if not already submitted, completed "Form for Financial Disclosure by Clinical Investigators"; (iv) Curricula vitae for principal investigator and all sub-investigators; (v) IRB approval of the Protocol; (vi) IRB approval of the patient informed consent form; (vii) list of IRB voting members or their DHHS numbers; (viii) invoice for initial IRB review and approval fee; and (ix) completed W9 form and, if applicable, Form 587. This fee is non-refundable and is inclusive of overhead. Medivation also agrees to cover all IRB fees including $1,500 not subject to overhead for the initial review. Fees will be paid upon receipt of invoice from on Institution.

Visit schedule:

Screening visits:	$ 2,425
Baseline Visits (1):	$ 1,755
Day 8:	$ 1,430
Day 29:	$ 1,580
Day 57:	$ 1,794
Day 85:	$ 1,677
Day 113:	$ 1,515
Day 141:	$ 1,515
Day 169:	$ 1,710
Safety F/U:	$ 1,300
	$16,701

Company shall pay $1,710 for the visits that will occur every 12 weeks after Day 169 until the patient leaves the trial.

Company shall pay up to $2,425 for screen failures based upon completed procedures. Company shall pay Unscheduled visits based upon procedures completed up to $1,333.

Company shall pay for survival follow-up visits $130 beginning 2 months after last visits and every 2 months after as long as patient survives.

Company shall pay a one-time pharmacy set up and close out fee of $1,300 for both pharmacies that are involved in the study (#1 & #2)
Company shall pay a monthly pharmacy maintenance cost of $75 for each pharmacy involved in the trial.
Company shall pay $25 to report outside AEs to the IRB
All fees are inclusive of overhead and shall be billed by the Institution.



SCHEDULE 1

Exhibit C

See Attached Master Budget inclusive of overhead

Exhibit C has been added to reflect payment for subjects as they transfer into Protocol Amendment 4. Prior to migrating, cost will remain consistent with original Exhibit B.

Company shall also reimburse Institution for subsequent annual IRB renewal fees, and, if applicable, fees for IRB review and approval of each material Protocol amendment.

Visit schedule:

Visit schedule Placebo:

Screening visits:	$ 1008
Day (1):	$ 748
Week 4:	$ 586
3 months:	$ 715
6 months:	$ 715
9 months:	$ 715
12 months:	$ 715
Safety F/U:	$ 650
	$5852

Visit schedule Active:

Day (1):	$ 878
3 months:	$ 715
6 months:	$ 715
9 months:	$ 715
12 months:	$ 715
Safety F/U:	$ 650
	$4388

Company shall pay $715 every 12 weeks until trial has completed.

Company shall pay screen failures based upon procedures completed up to $1008.

Company shall pay unscheduled visits based upon procedures completed up to $650.

Company shall pay for survival follow-up visits $130 beginning after subject has completed trial and safety follow up visit and every 3 months as required per protocol.

Institution shall attempt to send bills for applicable pass-throughs within 90 days to sponsor for reimbursement.

	Screening Visit (For Placebo Patients Only)	Day 1 Active	Day 1 Placebo	Week 4 (For Placebo Patients Only)	Every 12 Weeks Study Visit	Every 12 Weeks Study Visit	Every 12 Weeks Study Visit	Every 12 Weeks Study Visit	Safety F/U[a]	Unscheduled Visit[b]	Long-Term F/U (Every 12 Weeks) Phone call
Window (days)	**≤30 days prior to Week 1**			**±7**	**±7**	**±7**	**±7**	**±7**	**±7**	**n/a**	**±7**
Informed Consent	100	100									
Eligibility for Cross-Over Therapy	50										
Vital Signs[c]	SoC	SoC	SoC	SoC	SoC	SoC	SoC	SoC	SoC	SoC	
Brief Physical Examination, Weight[d]	100	100	100	101	100	100	100	100	100	100	
MUGA/ECHO[e]	X							X			
Clinical Labs[f]	75	75	75	75	75	75	75	75	75	75	
ECGs[g]	100										
Adverse Events[h]		50	50	50	50	50	50	50	50	50	
Concomitant Medications	50	50	50	50	50	50	50	50	50	50	
Study Drug Dispensing (3 bottles)		50	50		50	50	50	50			
LTFU Overall Survival Assessment[k]											100
SC/Data entry time	150	150	150	75	125	125	125	125	125	125	
PI Time	100	100	100	100	100	100	100	100	100	100	
Total	775	675	575	451	550	550	550	550	500	500	100
Overhead 30%	233	203	173	135	165	165	165	165	150	150	30
Total	1008	878	748	586	715	715	715	715	650	650	130

Placebo	1008	NA	748	586	715	715	715	715	650	650	130
Active	NA	878	NA	NA	715	715	715	715	650	650	130

Total amount through one year plus Safety FU visit

Placebo Pt total: 5651 For subjects who stay on trial through WK 48 + Safety F/U

Active Pt total: 4388

To be Invoiced

NCT Number
NCT00974311

Account	Account Description	Dept	Fund Type	Source	PC Bus Unit	Project	Activity	Budget	Expense	Encumbrance	Pre-Encumbrance	Available Budget*	Percent Available
501000	Salary Budget	415021	442	441010	20100	4782	1	25,236.72	25,236.72	0	0	0	0
508000	Fringe Benefits Budget	415021	442	441010	20100	4782	1	7,291.08	7,291.08	0	0	0	0
510000	Other Mat & Supp Budget	415021	442	441010	20100	4782	1	12,941.72	12,941.72	0	0	0	0
524000	Sub-recipient Payments Budget	415021	442	441010	20100	4782	1	2,000.00	2,000.00	0	0	0	0
568000	Facil and Admin Budget	415021	442	441010	20100	4782	1	14,265.65	4,521.46	0	0	9,744.19	68.31
569000	Grant Restricted Budget	415021	442	441010	20100	4782	1	80.83	0	0	0	80.83	100
587000	Non-Operating Expense Budget	415021	442	441010	20100	4782	1	0	9,744.18	0	0	-9,744.18	0

Study Approved to Enroll	10	
Total enrollment to Date	4	Note: Out of 4 enrolled, 2 failed screening and did not proceed to receive study treatment